Indianapolis: Roche has announced that the United States Food and Drug Administration (FDA) has cleared its Elecsys pTau181 test, the blood-based biomarker (BBM) test indicated as an aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in the primary-care setting.

The Elecsys pTau181 test is intended for patients ages 55 and older presenting with signs, symptoms or complaints of cognitive decline. It measures phosphorylated Tau (pTau) 181 protein in human plasma, a key biomarker for Alzheimer's pathology, including amyloid plaque and tau aggregate pathology.

Developed in collaboration with Eli Lilly and Company, this minimally invasive test provides clinicians with information that can help identify patients in early stages of cognitive declin

See Full Page